TBX4 variants and pulmonary diseases: getting out of the 'Box'

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)
47 Downloads (Pure)

Abstract

Purpose of review

In 2013, the association between T-Box factor 4 (TBX4) variants and pulmonary arterial hypertension (PAH) has first been described. Now - in 2020 - growing evidence is emerging indicating that TBX4 variants associate with a wide spectrum of lung disorders.

Recent findings

TBX4 variants are enriched in both children and adults with PAH. The clinical phenotype associated with a TBX4 variant seems to be milder than that in other PAH-associated gene mutations. Further, TBX4 variants have increasingly been associated with a variety of clinical and histopathological phenotypes, including lethal developmental parenchymal lung diseases such as not only acinar dysplasia in neonates, but also less outspoken parenchymal lung diseases in children and adults.

Summary

The clinical phenotype of a TBX4 variant has recently been recognised to expand from bone disorders to different types of lung diseases. Recent data suggest that variants of TBX4, a transcription factor known to be an important regulator in embryonic development, are not rare in both children and adults with PAH and/or developmental parenchymal lung diseases.

Original languageEnglish
Pages (from-to)277-284
Number of pages8
JournalCurrent Opinion in Pulmonary Medicine
Volume26
Issue number3
DOIs
Publication statusPublished - May-2020

Keywords

  • lung disease
  • pulmonary arterial hypertension
  • T-Box factor 4
  • GROWTH-FACTOR
  • ARTERIAL-HYPERTENSION
  • BETA-RECEPTOR
  • GENE
  • EXPRESSION
  • MUTATIONS
  • FGF10
  • CHILDREN
  • IDENTITY
  • CLONING

Cite this